

---

## References

**Abu J and Davies Q.** Endocervical curettage at the time of colposcopic assessment of the uterine cervix. *Obstet Gynecol Surv* 2005 May; 60(5): 315-20.

**Advisory Committee on Immunization Practices.** June 29–30, 2006. Record of the Proceedings. Human Papillomavirus Vaccine. P5-6. (Website) available at <http://www.pubmedcentral.nih.gov/redirect3.cgi?> Accessed 2007.

**American Cancer Society.** Cancer Facts & Figures. Atlanta 2008. (Website) available at [http:// www.cancer.org](http://www.cancer.org).

**American Society for Colposcopy and Cervical Pathology.** The cervix: histology of the normal Cervix: practice recommendation: Practice-Management Materials. (Website) available at: <http://www.asccp.org/edu/practice/ cervix>. Accessed 2004.

**Andersen ES and Nielsen K.** Adenocarcinoma in situ of the cervix: a prospective study of conization as definitive treatment. *Gynecol Oncol* 2002; 86:365-9.

**Andrews S, Hernandez E and Miyazawa K.** Paired Papanicolaou smears in the evaluation of atypical squamous cells. *Obstet Gynecol* 1998; 73 (5 Pt 1): 747-50.

**Anne-Marie Lozeau, Sarina Schrager and Reed Lowrie.** What is the best treatment for CIN 2 or 3? *The Journal of Family Practice* 2008. (Website) available at: <http://www.jfponline.com/default.asp?Log off=1>.

---

**Answers Corporation.** Spectroscopy. (Website) available at:  
<http://www.answers.com/topic/spectroscopy>. Accessed 2008.

**Anuja J, Patricia J Eifel, J Taylor Wharton, and Guillermo Tortolero-Luna.** Neoplasms of the Cervix. Section 30: Female Reproductive Organs. Cancer Medicine 6th Edition. Holland.Frei, 2003.

**Apgar S Spitzer M, Brotzman GL and Ignatavicius DD.** Colposcopy: principles and practice: an integrated textbook and atlas. 1st Edition. WB Saunders Company, 2002.

**Ashrafi GH, Haghshenas MR, Marchetti B, O'Brien PM and Campo MS.** E5 protein of human papillomavirus type 16 selectively downregulates surface HLA class I. Int J Cancer 2005;113:276-83.

**August N.** Cervicography for evaluating the atypical Papanicolaou smear. J Reprod Med 1991; 36: 89.

**Ault KA, Villa LL Giuliano AR, et al.** Immunologic responses following administration of a vaccine targeting human papillomavirus types 6, 11, 16, and 18. Vaccine 2006; 24:5571-83.

**Baggish MS and Baggish M.** Colposcopy of the cervix, vagina, and vulva: a comprehensive textbook. Mosby, Inc.; 2003.

**Baldauf JJ, Dreyfus M, Lehmann M, Ritter J and Philippe E.** Cervical cancer screening with cervicography and cytology. Eur J Obstet Gynecol Reprod Biol. 1995 Jan; 58(1):33-9.

---

**Barbara SA and Lauren ZM.** The 2001 Bethesda System Terminology. Journal of American Academy of Family Physician 2003 Nov; 68(10).

**Barnabas RV, Laukkanen P, Koskela P, et al.** Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modelling analyses. PLoS Med 2006; 3:138.

**Basu P, Sankaranarayanan R, Mandal R, Roy C, Das P, Choudhury D, Datta K, Karamakar S, Tsu V, Chakrabarti RN, and Siddiqi M.** Evaluation of downstaging in the detection of cervical neoplasia in Kolkata, India. Int J Cancer 2002 Jul; 100(1): 92-6.

**Basu PS, Sankaranarayanan R, Mandal R, Roy C, Das P, Choudhury D, et al.** Visual inspection with acetic acid and cytology in the early detection of cervical neoplasia in Kolkata, India. Int J Gynecol Cancer 2003; 13:626-32.

**Belinson JL, Pretorius RG, Zhang WH, Wu LY, Qiao YL and Elson P.** Cervical cancer screening by simple visual inspection after acetic acid. Obstet Gynecol 2001; 98: 441-444.

**Bell MC and Alvarez RD.** Chemoprevention and vaccines: a review of the non surgical options for the treatment of cervical dysplasia. Int J Gynecol Cancer 2005; 15:4-12.

**Benedet JL, Odicino F, Maisonneuve P, et al.** Carcinoma of the cervix uteri. International Journal of Gynecology and Obstetrics 2003; 83(supplement 1): 41-78.

---

**Benjamin I and Echols L.** The Pap test: Cervical Changes and Helath-Care. (Website) available at: [http://www.oncolink.upenn.edu/types/article.cfm?c=6 & s=17 &ss 131 & id=6027](http://www.oncolink.upenn.edu/types/article.cfm?c=6&s=17&ss=131&id=6027). Accessed 2001.

**Berdichevsky L, Karmin R and Chuang L.** Treatment of high-grade squamous intraepithelial lesions a 2- versus 3-step approach. *Am J Obstet Gynecol* 2004; 190: 1424–1426.

**Bibbo M .**Comprehensive cytology, Ectocervix. WB Saunder company Harcourt Brace Jovanorich, Inc. Philadelphia, 1991; p 153.

**Bibbo M, Klump WJ, DeCecco J, and Kovatich AJ.** Procedure for immunocytochemical detection of P16INK 4A antigen in thin-layer, liquid-based specimens *Acta Cytol* 2002; 46: 25-29.

**Bierman R, Ho GY, Beardsley L, Chang CJ and Burk RD.** Natural history of cervicovaginal papillomavirus infection in young women. *N Engl J Med* 1998; 338: 423-8.

**Blumenthal P.** Discussion of aided visual inspection. In the proceedings from a working meeting on cervical cancer prevention, screening and treatment. Program for appropriate technology in health for Nicholson Street. In collaboration with AVSC International: Montreal Quebec; 1994.

**Bosch FX and de Sanjose S. Human papillomavirus, cervical cancer-burden,** and assessment of causality. *Journal of the national cancer institute Monographs* 2003; 1: 3- 13.

**Brandsma JL, Shlyankevich M, Zhang L, et al.** Vaccination of rabbits with an adenovirus vector expressing the papillomavirus E2 protein leads to

---

clearance of papillomas and infection. *Journal of Virology* 2004; 78:116-123.

**Brinck U, Jakob C, Bau O and Fuzesi L.** Papillary squamous cell carcinoma of the uterine cervix: report of three cases and a review of its classification. *Int J Gynecol Pathol* 2000; 19: 231-235.

**Brown LJ and Wells M.** Cervical glandular atypia associated with squamous intraepithelial neoplasia: a premalignant lesion? *J Clin Pathol* 1986; 39: 22-28.

**Bryson P, Stulberg R, Shepherd L, Mc Lelland K, Jeffrey J, et al.** Is electrosurgical loop excision with negative margins sufficient treatment for cervical ACIS? *Gynecol Oncol* 2004; 93: 465-468.

**Burghardt E, Pickel H, Girardi F.** Primary care colposcopy: textbook and atlas, 1st Edition. Thieme Medical Publishers; 2002.

**Burk RD, Ho GY, Beardsley L, Lempa M, Peters M, Bierman R ,et al.** Sexual behavior and partner characteristics are the predominant risk factors for genital human papillomavirus infection in young women. *J Infect Dis* 1996; 174:679-89.

**Carol EB, Edward M Beadle, Dennis Bealka, et al.** Evaluation and Management of Abnormal Pap Smears: A Primer for primary care providers. Prepared by The Sage Screening Program Health Promotion and Chronic Disease Division. (website) available at: [www.MNSage.com](http://www.MNSage.com). Revised: July 2006.

---

**Carter JJ, Koutsky LA, Wipf GC, Christensen ND, Lee SK, Kuypers J, et al.** The natural history of human papillomavirus type 16 capsid antibodies among a cohort of university women. *J Infect Dis* 1996; 174: 927.

**Christine HH.** Premalignant and malignant disorders of the uterine cervix. *Current Obstetric and Gynecologic Diagnosis and Treatment* 2003; 47: 894-904.

**CIGNA Health Corporation.** Cervical Cancer Screening Technologies. *CIGNA HealthCare Coverage Position* 2007; 127: 4, 7, 9.

**Ciuffo G.** Imnfesto positivo con filtrato di verruca volgare. *Giorn Ital Mal Venereol* 1907; 48:12-7.

**Clifford G, Franceschi S, Diaz M, et al.** Chapter 3: HPV type-distribution in women with and without cervical neoplastic diseases. *Vaccine* 2006; 24 (Suppl 3): 26-34.

**Coleman DV, Evans DMD, and Baker R.** *Biopsy Pathology and Cytology of the cervix*, 2nd Edition. Co-published in the USA by Oxford Unviersity Press Inc. New York; 1999.

**Collier T, Shen P, de Pradier B, et al.** Near real time confocal microscopy of amelanotic tissue: dynamics of aceto-whitening enable nuclear segmentation. *Opt Express* 2000; 6:40-48.

**Collier T, Lacy A, Malpica A, Follen M, Richards-Kortum R,et al.** Near real time confocal microscopy of amelanotic tissue: detection of dysplasia in ex-vivo cervical tissue. *Acad Radiol* 2002; 9:504-512.

---

**Connor JP.** Noninvasive cervical cancer complicating pregnancy. *Obstet Gynecol Clin North Am* 1998; 25:331-42.

**Coppleson M.** Early invasive squamous and adenocarcinoma of the cervix (FIGO stage 1a) clinical features and management. In: Coppleson, M (Ed) *Gynaecological Oncology* 1992; Vol 1. 2nd Edition, Churchill Livingstone, Edinburgh.

**Costa RLR, Villa LL Petta CA, et al.** High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 virus-like particle vaccine through 5 years of follow-up. *Br J Cancer* 2006; 95:1459-66.

**Dalstein V, Riethmuller D, Pretet JL, Le Bail Carval K, Sautiere JL, Carbillet JP, et al.** Persistence and load of high-risk HPV are predictors for development of high-grade cervical lesions: a longitudinal French cohort study. *Int J Cancer* 2003; 106(3): 396-403.

**Dawar M, Shelley Deeks, and Simon Dobson.** Human papillomavirus vaccines launch a new era in cervical cancer prevention. *Canadian Medical Association Journal* 2007 August; 177(5): 456-461.

**DeFrancesco M, Gargiolo F, Ciravolo G, Salinaro F, Manca N, et al.** Detection and genotyping of human papillomavirus in cervical samples from Italian patients. *J Med Virol* 2005; 75:588-92.

**Denny L, Kuhn L, Pollack A and Wright TC Jr.** Direct visual inspection for cervical cancer screening: An analysis of factors influencing test performance. *Cancer* 2002; 94:1699-707.

---

**Diaz-Arrastia C, Arany I, Robazetti SC, Dinh TV, Gatalica Z, Tyring SK, et al .** Clinical and molecular responses in high-grade intraepithelial neoplasia treated with topical imiquimod 5%. *Clin Cancer Res* 2001; 7: 3031-3.

**Donna Dehn, Kathleen C Torkko and Kenneth R Shroyer.** Human Papillomavirus Testing and Molecular Markers of Cervical Dysplasia and Carcinoma. *Cancer (Cancer Cytopathology)* 2007 Feb; 111(1): 1-14.

**Doorbar J.** The papillomavirus life cycle. *J Clin Virol* 2005; 32 (Suppl 1): 7-15.

**Drezek RA, Rebecca Richards-Kortum, Molly A Brewer, Michael S Feld, Constantinos Pitris, Alex Ferenczy , Mark L Faupel and Michele Follen.** Optical Imaging of the Cervix. *Cancer* 2003; 98(Suppl 9):2015-27.

**Egawa K.** Do human papillomaviruses target epidermal stem cells? *Dermatology* 2003; 207:251-4.

**EL-Ghobashy AA, Shaabm AM, Herod JJ and Herrington CS.** The pathology and management of endocervical glandular neoplasia. *Int J Gynaecol Cancer* 2005; 15: 583-592.

**Evans DMD, Hudson EA, Brown CL, Boddington MM, Hughes HC, Mackenzie EFD, and Marshall T.** Terminology in Gynecological cytopathology. Report of the working party of the British Society for Clinical Pathology. *J Clin Pathol* 1996; 39: 933-944.

**Ferenczy A and Franco EL.** Cervical cancer screening beyond the year 2000. *Lancet Oncol* 2001; 2: 27-32.

---

**FIGO CCo.** Staging announcement. *Gynecol Oncol* 1986; 25: 383-385.

**Forslund O, Antonsson A, Higgins G, et al.** Nucleotide sequence and phylogenetic classification of candidate human papillomavirus type 92. *Virology* 2003; 312:255-60.

**Franco EL, Villa LL, Sobrino JP, Prado JM, Rousseau MC, Desy M and Rohan TE.** Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high-risk area for cervical cancer. *J Infect Dis* 1990; 180: 1415-1423.

**Franco EL, Durate-Franco E, and Ferenczy A.** Cervical cancer: Epidemiology, prevention, and role of human papillomavirus infection. *Can Med Assoc J* 2001; 164: 1017-1025.

**Franco E and Ferenczy A.** Cancer precursors: Epidemiology, detection and prevention. *Cervix* (Eds Franco EL, Rohan TE) New York: Springer-Verlag, 2002: 249-286.

**Franco E and Ferenczy A.** Persistent human papillomavirus infection and cervical neoplasia. *Lancet Oncol* 2002; 3:11-16.

**Francois Coulee, Danielle Rouleau, Alex Ferenczy and Eduardo Franco.** The laboratory diagnosis of genital human papillomavirus infections. *Can J Infect Dis.* 2005; 16(2): 83-91.

**Frappart L, Fontanière B and Sankaranarayanan Autumn R.** Histopathology and cytopathology of the Uterine Cervix – Digital Atlas, 2004.

---

**Friedell G, McKay D.** Adenocarcinoma in situ of the endocervix. *Cancer* 1953; 6: 887-897.

**Future II Study Group.** Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomized clinical trials. *Lancet* 2007; 369:1861-8.

**Future II Study Group.** Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. *N Engl J Med* 2007; 356: 1915-27.

**Gall SA, Teixeira J, Wheeler CM, et al.** Substantial impact on precancerous lesions and HPV infections through 5.5 years in women vaccinated with the HPV-16/18 L1 VLP ASO4 candidate vaccine. American Association for Cancer Research Annual Meeting; 2007 Apr 17; Los Angeles.

**Garland SM, Hernandez-Avila M, Wheeler CM, et al.** Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. *N Engl J Med* 2007; 356:1928-43.

**Georgakoudi I, et al.** Trimodal spectroscopy for the detection and characterization of cervical precancers in vivo. *Am J Obstet Gynecol*, 2002; 186(3): 374-82.

**Gisela Dallenbach-Hellweg, Magnus von Knebel Doeberitz, and Marcus J Trunk.** Color Atlas of Histopathology of the Cervix Uteri 2nd Edition. Heidelberg, 2005.

---

**Gnanamony M, Peedicayil A, Abraham P.** An overview of human papillomaviruses and current vaccine strategies. *Indian J Med Microbiol* 2007; 25:10-7.

**Green JA, Kirwan JM, Tierney JF, Symonds P, Fresco L, Collingwood M and Williams C.** Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: a systematic review and meta-analysis. *Lancet* 2001; 358: 781-786.

**Gupta PK Majumder SK, Uppal A, et al.** In-vitro diagnosis of human uterine malignancy using N2 laser induced autofluorescence spectroscopy. *Curr Sci* 1996; 70:833-6.

**Gurjar RS, et al.** Imaging human epithelial properties with polarized light-scattering spectroscopy. *Nat Med* 2001; 7(11): 1245-8.

**Harper DM, Franco EL, Wheeler C, et al.** Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomized controlled trial. *Lancet* 2004; 364:1757-65.

**Harper DM, Franco EL, Wheeler C, et al.** Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomized controlled trial. *Lancet* 2006; 367:1247-55.

**HAYES Medical Technology Directory.** Magnified chemiluminescent visual examination (Speculoscopy) as an adjunct to Pap testing for cervical cancer screening. Lansdale, PA: HAYES, Inc. Nov 25

---

**Hemminki K, Li X and Vaittinen P.** Time trends in the incidence of cervical and other genital squamous cell carcinomas and adenocarcinomas in Sweden, 1958–1996. *Eur J Obstet Gynecol Reprod Biol* 2002; 101:64–9.

**Herrington CS, El-Ghobashy AA.** Diagnosis and management of pre-invasive cervical glandular neoplasia. *Recent Advances in Obstetrics and Gynaecology* 2005; 17:231-230.

**Holowaty P, Miller AB, and Rohan T.** Natural history of dysplasia of the uterine cervix. *J Natl Cancer Inst* 1999; 91: 252-258.

**Honey K.** HPV vaccine gets a shot in the arm. *J Clin Invest* 2006; 116 (12): 3087.

**Hornung R, et al.** Quantitative near-infrared spectroscopy of cervical dysplasia in vivo. *Hum Reprod* 1999; 14(11): 2908-16.

**Howard M, Sellors J and Lytwyn A.** Cervical intraepithelial neoplasia in women presenting with external genital warts. *CMAJ* 2002; 166:598-599.

**Hutchinson ML, Zahniser DJ, Sherman ME, Herrero R, Alfaro M and Bratti MC.** Utility of liquid based cytology for cervical carcinoma screening: Results of a population-based study conducted in a region of Costa Rica with a high incidence of cervical carcinoma. *Cancer* 1999; 87: 48-55.

**Hymel PA.** Decreasing risk: Impact of HPV vaccination of outcomes. *American Journal of Managed Care* 2006: 473-483.

**Inglis S, Shaw A and Koenig S.** Chapter 11: HPV vaccines: Commercial research & development. *Vaccine* 2006; 24(Suppl 3): 99-105.

**Institut de recherches cliniques de Montréal.** (Website) available at [http://rds.yahoo.com/\\_ylt=A0WTefavO2hJSeIARUyjbkF/SIG=124fgadjl/EXP=1231654191/\\*\\*http://www.ircm.qc.ca/microsites/hpv/en/390.html](http://rds.yahoo.com/_ylt=A0WTefavO2hJSeIARUyjbkF/SIG=124fgadjl/EXP=1231654191/**http://www.ircm.qc.ca/microsites/hpv/en/390.html)  
Accessed 2007.

**International Agency for Research of Cancer.** Cervical cancer screening. A practical manual of visual screening for cervical neoplasia 2005; Chapter 1.

**Jacob M, Bradley J and Barone MA.** Human papillomavirus vaccines: what does the future hold for preventing cervical cancer in resource-poor settings through immunization programs? *Sex Transm Dis* 2005; 32:635-640.

**Jakobsson M, Gissler M, Sainio S, Paavonen J and Tapper AM.** Preterm delivery after surgical treatment for cervical intraepithelial neoplasia. *Obstet Gynecol* 2007; 109:309-13.

**John T III, Laurie K Thomas and Kenneth R Shroyer.** Human papillomavirus: molecular and cytologic/histologic aspects related to cervical intraepithelial neoplasia and carcinoma. *Human Pathology* 2008; 39: 154-166.

**Joura EA, Leodolter S, Hernandez-Avila M, et al.** Efficacy of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a

combined analysis of three randomized clinical trials. *Lancet* 2007; 369:1693-702.

**Juneja A, Sehgal A, Sharma S and Pandey A.** Cervical cancer screening in India: Strategies revisited. *Indian Journal of Medical Sciences* 2007; 61: 34-47.

**Kadish AS, Timmins P, Wang Y, Ho GY, Burk RD, Ketz J, et al.** Regression of cervical intraepithelial neoplasia and loss of human papillomavirus (HPV) infection is associated with cell-mediated immune responses to HPV type 16 E7 peptide. *Cancer Epidemiol Biomarkers Prev* 2002; 11: 483-8.

**Kalliala I, Nieminen P, Dyba T, Pukkala E and Anttila A.** Cancer free survival after CIN treatment: comparisons of treatment methods and histology. *Gynecol Oncol* 2007; 105:228-33.

**Kari PB, Marc R Laufer, et al.** Human Papillomavirus (HPV), HPV-Related Disease, and the HPV Vaccine. *Rev Obstet Gynecol* 2008; 1(1):2-10.

**Kartha VB Chidananda SM, Satyamoorthy K, Rai L and Manjunath AP.** Optical diagnosis of cervical cancer by fluorescence spectroscopy technique. *Int J Cancer* 2006; 119:139-45.

**Katherine EH, Susan AH, Kavita Nanda, John F Boggess and Dennis Zolnoun.** Screening for Cervical Cancer. Systematic Evidence Review prepared for Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 2002 Jan; 25:7-8.

---

**Kaufman RH, Adam E and Vonka V.** Human papillomavirus infection and cervical carcinoma. Clin Obstet Gynecol 2000; 43: 363-380.

**Koss LG, Durfee GR, et al.** Unusual patterns of squamous epithelium of the uterine cervix: cytologic and pathologic study of koilocytotic atypia. Ann N Y Acad Sci 1956; 63:1245-61.

**Kung-Liahng W.** Human Papillomavirus and Vaccination in Cervical Cancer. Taiwan J Obstet Gynecol 2007; 46(4):352-362.

**Kurian K, al-Nafussi A, et al.** Relation of Cervical glandular intraepithelial neoplasia to microinvasive and invasive adenocarcinoma of the uterine cervix: a study of 121 cases. J Clin Pathol 1999; 52: 112-117.

**Kurman RJ and Solomon D.** The Bethesda System for reporting cervical/vaginal cytological diagnosis: definitions, criteria, and explanatory notes for terminology and specimen adequacy. New York: Springer-Verlag, 1994.

**Kyrgiou M, Tsoumpou I, Vrekoussis T, et al.** The up-to-date evidence on colposcopy practice and treatment of cervical intraepithelial neoplasia: the Cochrane colposcopy and cervical cytopathology collaborative group (C5 group) approach. Cancer Treat Rev 2006; 32:516-23.

**Kyrgiou M, Koliopoulos G, Martin-Hirsch P, Arbyn M, Prendiville W, Paraskevaidis E, et al.** Obstetric outcomes after conservative treatment for intraepithelial or early invasive cervical lesions: systematic review and meta-analysis. Lancet 2006; 367:489-498.

---

**Lee TD.** Colposcopy: An Evidence-Based Update. The Journal of the American Board of Family Practice 2005; 18:383-392.

**Leslie Hanna.** Women and AIDS Cervical Intraepithelial Neoplasia published in the Bulletin of Experimental Treatments for AIDS June 1996 issue; by the San Francisco AIDS Foundation 1996.

**Leusley D and Leeson S.** Colposcopy and program management. Guidelines for the NHS Cervical Screening Program. NHSCSP; 2004.

**Li B and Dou QP.** Bax degradation by the ubiquitin/proteasome dependent pathway: involvement in tumor survival and progression. Proc Natl Acad Sci U S A 2000; 97:3850-5.

**Liaw KL, Hildesheim A, Burk RD, Gravitt P , Wacholder S, Manos MM, Scott DR, Sherman ME, Kurman RJ, Glass AG, Anderson SM and Schiffman M.** A prospective study of human papillomavirus (HPV) type 16 DNA detection by polymerase chain reaction and its association with acquisition and persistence of other HPV types. J Infect Dis 2001; 183: 8-15.

**Lindeque BG.** Management of cervical premalignant lesions. Best Practice and Research Clinical Obstetrics and Gynaecology 2005; 19(4): 545-561.

**Ljubojevic S.** The Human Papillomavirus vaccines. Acta dermatovenerol croat 2006; 14(3):208.

**Lonky NM, Felix JC, Naidu YM and Wolde-Tsadik G.** Triage of atypical squamous cells of undetermined significance with hybrid capture II:

---

colposcopy and histologic human papillomavirus correlation. *Obstet Gynecol* 2003 Mar; 101(3):481- 9.

**Luesley D, Shafi M and Jordan J.** Handbook of colposcopy, 1st Ed. Lippincott, Williams and Wilkins Publishers; 1996.

**Lyng FM, Faolin EO, Conroy J, Meade AD, Knief P, Duffy B, et al.** Vibrational spectroscopy for cervical cancer pathology, from biochemical analysis to diagnostic tool. *Exp Mol Pathol* 2007; 82(01):21-9.

**MacGrogor JE, LeselyA, FentomPM, et al.** screening for cervical cancer. *Recent Advances in Obstet and Gynecol* 1990; 16:127.

**Mahadevan-Jansen A, Mitchell MF, Ramanujam N, Malpica A, Thomsen S, Utzinger U, et al.** Near-infrared Raman spectroscopy for in vitro detection of cervical precancers. *Photochem Photobiol* 1998; 68:123-32.

**Manuel JB Sung Chang, Sun Young Park and Rebecca Richards-Kortum.** Multispectral digital colposcopy for in vivo detection of cervical cancer. *Optics Express* 2003 May; 11(10):1223-1236.

**Martin-Hirsch PL, Paraskevaidis E, Kitchener H.** Surgery for cervical intraepithelial neoplasia. *Cochrane Database Syst Rev* 2000 ;( 2) CD001318.

**Masters BR, Chance B.** Redox confocal imaging intrinsic fluorescent probes of cellular metabolism. In: Mason WT, editor. *Fluorescent and luminescent probes for biological activity*. London: Academic Press, 1993:44-57.

---

**Mayeaux EJ Jr. Colposcopy Atlas:** Colposcopic Terminology. Available at <http://lib-sh.lsuhs.edu/fammed/atlas/colpterm.html>. Accessed 2000.

**McCluggage WG.** Endocervical glandular lesions: controversial aspects and ancillary techniques. *J Clin Pathol* 2003; 56:164-173.

**Megevand E, Denny L, Dehaeck K, Soeters R and Bloch B.** Acetic acid visualization of the cervix: an alternative to cytologic screening. *Obstet Gynecol* 1996; 88:383-6.

**Melnikow J, Nuovo J, Willan AR, Chan BK and Howell LP.** Natural history of cervical squamous intraepithelial lesions: a meta-analysis. *Obstet Gynecol* 1998; 92(4 Pt 2): 727-735.

**Middleton K, Peh W, Southern S, et al.** Organization of human papillomavirus productive cycle during neoplastic progression provides a basis for selection of diagnostic markers. *J Virol* 2003; 77: 10186-201.

**Milbourne A, Park SY, Benedet JL, Miller D, Ehlen T, Rhodes H, et al.** Results of a pilot study of multispectral digital colposcopy for the in vivo detection of cervical intraepithelial neoplasia. *Gynecol Oncol* 2005; 99: 67-75.

**Molano M, Van den Brule A, Plummer M, Weiderpass E, Posso H, Arslan A, Meijer CJ ,et al.** HPV Study Group. Determinants of clearance of human papillomavirus infections in Colombian women with normal cytology: a population-based, 5-year follow up-study. *Am J Epidemiol* 2003; 158(5):486-94.

**Moscicki AB, Hills N, Shiboski S, Powell K, Jay N, Hanson E, Miller S, Clayton L, Farhat S, Broering J, Darragh T, and Palefsky J.** Risks for incident human papillomavirus infection and low grade squamous intra-epithelial lesion development in young females. *JAMA* 2001; 285:2995-3002.

**Moscicki AB, Shiboski S, Hills NK, et al.** Regression of low-grade squamous intra-epithelial lesions in young women. *Lancet* 2004; 364:1678-83.

**Murali KC, GD Sockalingum, MS Vidyasagar, M Manfait, Donald J Fernanades, BM Vadhiraaja, K Maheedhar.** An overview on applications of optical spectroscopy in cervical cancers. *Journal of Cancer Research and Therapeutics* 2008;4(1):26-36.

**Nakagawa M, Stites DP, Farhat S, Sisler JR, Moss B, Kong F, et al.** Cytotoxic T lymphocyte responses to E6 and E7 proteins of human papillomavirus type 16: Relationship to cervical intraepithelial neoplasia. *J Infect Dis* 1997; 175:927-31.

**Nakagawa M, Stites DP, Palefsky JM, Kneass Z and Mosciki AB.** CD4-positive and CD8- positive cytotoxic T lymphocytes contribute to human papillomavirus type 16 E6 and E7 responses. *Clin Diagn Lab Immunol* 1999; 6: 494-8.

**Nanda K, McCrory DC, Myers ER, Bastian LA, Hasselblad V, Hickey JD, et al.** Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: A systematic review. *Ann Intern Med* 2000; 132: 810-819.

---

**National Cancer Institute Workshop.** The 1988 Bethesda System for reporting cervical/vaginal cytologic diagnosis. JAMA 1989; 262: 931-934.

**National Cancer Institute Workshop.** The Bethesda System for reporting cervical/vaginal cytologic diagnoses: revised after the second National Cancer Institute Workshop, April 29-30, 1991. Acta Cytol 1993; 37: 115-124.

**National Cancer Institute.** The Pap Test Questions and Answers, 2001. (Website) available at [http://cis.nci.nih.gov/fact/5\\_16.htm](http://cis.nci.nih.gov/fact/5_16.htm). Accessed. 2001.

**NHSCSP.** Colposcopy and Programme Management. Sheffield: NHS Cervical Screening Programme, 2004.

**NHSCSP TRCoPat.** Achievable Standards, Benchmarks for reporting, and criteria for evaluating cervical cytopathology. NHSCSP Publication 2000; No 1.

**Olsson SE, Villa LL, Costa RLR, et al.** Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle(VLP) vaccine. Vaccine 2007; 26:4931-39.

**Ostor AG.** Natural history of cervical intraepithelial neoplasia: a critical review. Int J Gynecol Pathol 1993; 12: 186-192.

**Ostor AG.** Pandora's box or Ariadne's thread? Definition and prognostic significance of microinvasion in the uterine cervix. Squamous lesions. Pathol Annu 1995; 30 (Pt 2): 103-136.

---

**Ostor AG, Rome R, Quinn M, et al.** Microinvasive adenocarcinoma of the cervix: a clinicopathologic study of 77 women. *Obstet Gynecol* 1997; 89:88–93.

**Ostor AG.** Early invasive adenocarcinoma of the uterine cervix. *Int J Gynecol Pathol* 2000; 19:29-38.

**Oxford Health Plans.** Medical and Administrative Policies: Cervicography and Speculoscopy for Cervical Cancer Screening. (Website) available-at [https://www.oxhp.com/secure/policy/cervicography\\_408.html](https://www.oxhp.com/secure/policy/cervicography_408.html). Accessed 2008.

**Paavonen J, Jenkins D, Bosch FX, et al.** Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. *Lancet* 2007; 369:2161-70.

**Pagliusi SR and Aguado MT.** Efficacy and other milestones for human papillomavirus vaccine introduction. *Vaccine* 2004; 23:569-78.

**Pagliusi SR, Dillner J, Pawlita M, et al.** Chapter 23: International standard reagents for harmonization of HPV serology and DNA assays: an update. *Vaccine* 2006; 24(Suppl 3):193-200.

**Palsson S, Stenram U, Thompson MS, Vaitkuviene A, Poskiene V, Ziobakiene R, et al.** Methods for detailed histopathological investigation and localization of biopsies from cervix uteri to improve the interpretation of autofluorescence data. *J Environ Pathol Toxicol Oncol* 2006; 25:321-40

---

**Parashari A, Singh V, Sehgal A, Satyanarayana L, Sodhani P, Gupta MM.** Low cost technology for screening of uterine cervical cancer. Bull WHO 2000; 78:964-7

**Paraskevaïdis E, Arbyn M, Sotiriadis A, et al.** The role of HPV DNA testing in the follow-up period after treatment for CIN: a systematic review of the literature. Cancer Treat Rev 2004; 30:205-11.

**Persad VL, Pierotic MA, Guijon FB.** Management of cervical neoplasia: a 13-year experience with cryotherapy and laser. J Low Genit Tract Dis 2001; 5:199-203.

**Peyton CL, Schiffman M, Lorincz AT, et al.** Comparison of PCR- and hybrid capture-based human papillomavirus detection systems using multiple cervical specimen collection strategies. J ClinMicrobiol 1998; 36:3248-54.

**Peyton CL, Gravitt PE, Hunt WC, Hundley RS, Zhao M, et al.** Determinants of genital human papillomavirus detection in a US population. J Infect Dis 2001; 183(11):1554-64.

**Philip J, William T, et al.** Preinvasive diseases of the cervix. Clinical Gynecologic Oncology 1997; 1: 1-31.

**Proctor DT.** Staining techniques in clinical cytopathology (Eds DV Coleman and PA chaomen), Butterworths, London, 1989; Chapter 6.

**Prusty BK and Das BC.** Constitutive activation of transcription factor AP-1 in cervical cancer and suppression of human papillomavirus (HPV)

transcription and AP-1 activity in HeLa cells by curcumin. *Int J Cancer* 2005; 113: 951-60.

**Reisinger KS, Block SL, Lazcano-Ponce E, et al.** Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents. A randomized controlled trial. *Pediatr Infect Dis J* 2007; 26:201-9.

**Renshaw AA, Mody DR, Lozano RL, Volk EE, Walsh MK, Davey DD and Birdsong GG.** Detection of adenocarcinoma in situ of the cervix in Papanicolaou tests: comparison of diagnostic accuracy with other high-grade lesions. *Arch Pathol Lab Med* 2004; 128:153-7.

**Robichaux AV.** Raman Spectroscopy for in vivo, non-invasive detection of dysplasia of the cervix. Dissertation Submitted to the Faculty of the Graduate School of Vanderbilt University in partial fulfillment of the requirements for the degree of Doctor of Philosophy in Biomedical Engineering May 2004, Nashville, Tennessee.

**Sankaranarayanan R and Ramani SW.** A Practical Manual on Visual Screening for Cervical Neoplasia. IARC Technical Publication No. 41, IARC Press, Lyon .2003.

**Sankaranarayanan R, Chatterji R, Shastri SS, Wesley RS, Basu P, Mahe C, et al.** Accuracy of human papillomavirus testing in primary screening of cervical neoplasia: Results from a multicenter study in India. *Int J Cancer* 2004; 112:341-7.

---

**Sankaranarayanan R, Basu P, Wesley RS, Mahe C, Keita N, Mbalawa CC, et al.** IARC Multicentre Study Group on Cervical Cancer Early Detection. Accuracy of visual screening for cervical neoplasia: Results from an IARC multicentre study in India and Africa. *Int J Cancer* 2004; 110:907-13.

**Saslow D, Runowicz CD, Solomon D, Moscicki AB, Smith RA, Eyre HJ, et al.** American Cancer Society Guidelines for the early detection of cervical neoplasia and cancer. *CA Cancer J Clin* 2002; 52(3): 342-362.

**Saslow D, Philip E Castle, J Thomas Cox, Diane D. Davey, Mark H Einstein, Daron G Ferris, et al.** American Cancer Society Guidelines for Human Papillomavirus (HPV) Vaccine Use to Prevent Cervical Cancer and Its Precursors. *CA Cancer J Clin* 2007; 57:7-28.

**Schlecht NF, Kulaga S, Robitaille J, Ferreira S, Santos M, Miyamura RA Duarte-Franco E, Rohan TE, Ferenczy A, Villa LL, and Franco EL.** Persistent Human Papillomavirus Infection as a Predictor of Cervical Intraepithelial Neoplasia. *Journal of the American Medical Association (JAMA)* 2002; 286: 3106-3114.

**Schneider DL, Thomas C Wright, Mark Spitzer, Nilanjan Hatterjee, Sholom Wacholder, Rolando Herrero, Maria C Bratti, et al.** Can cervicography be improved? An evaluation with arbitrated cervicography interpretations. *Am J Obstet Gynecol* 2002; 187:15-23.

**Schomacker KT, Frisoli JK, Compton CC, et al.** Ultraviolet laser-induced fluorescence of colonic tissue: basic biology and diagnostic potential. *Lasers Surg Med.* 1992; 12:63-78.

---

**Sellors JW, Jeronimo J, Sankaranarayanan R, Wright TC, Howard M and Blumenthal PD.** Assessment of the cervix after acetic acid wash: inter-rater agreement using photographs. *Obstet Gynecol* 2002; 99:635-40.

**Sellors JW, Sankaranarayanan R.** Colposcopy and treatment of cervical intraepithelial neoplasia, a beginners' manual. Intl. Agency for Research on Cancer, 2003.

**Shafi M I, Luesley DM, Jordan JA, Dunn JA, Rollason TP and Yates M.** Randomised trial of immediate versus deferred treatment strategies for the management of minor cervical cytological abnormalities. *Br J Obstet Gynaecol* 1997; 104: 590-594.

**Shastri SS, Dinshaw K, Amin G, Goswami S, Patil S, Chinoy R, et al.** Concurrent evaluation of visual, cytological and HPV testing as screening methods for the early detection of cervical neoplasia in Mumbai, India. *Bull WHO* 2005; 83:186-94.

**Sikorski M, Zrubek H.** Recombinant human interferon gamma in the treatment of cervical intraepithelial neoplasia (CIN) associated with human papillomavirus (HPV) infection. *Eur J Gynaecol Oncol* 2003; 24: 147-50.

**Singer A and Monaghan J.** Lower Genital Tract Precancer Colposcopy, Pathology and Treatment, 2nd Edition, Blackwell Science, Oxford, 2000.

**Snoeck R, Noel JC, Muller C, De Clercq E and Bossens M.** Cidofovir, a new approach for the treatment of cervical intraepithelial neoplasia grade III (CIN III) *J Med Virol* 2000; 60:205-9.

---

**Solomon D, Davey D, Kurman R, Moriarty A, Connor D, Prey M, Raab S, Sherman M , Wilbur D, Wright Jr T, and Young N.** The 2001 Bethesda system. Terminology for reporting results of cervical cytology. JAMA 2002; 287: 2114-2119.

**Soutter P and Soutter WP.** A practical guide to colposcopy (Oxford Medical Publications). Oxford University Press; 1997.

**Spitzer M.** Cervical screening adjuncts: recent advances. Am J Obstet Gynaecol 1998; 179:544-556.

**Stanley M.** Human papillomavirus and cervical carcinogenesis. Best practice and Research clinical obstetric and Gynecology 2001; 15: 663-676.

**Stanly M.** Genital human papillomavirus infection: current and prospective therapies. JNCL Monographs 2003; 31: 117- 124.

**Stanly M.** HPV Vaccines. Best practice and Research clinical obstetric and Gynecology 2006; 20 (2): 279- 293.

**Stanley M.** Prophylactic HPV vaccines: Two HPV L1 VLP vaccines have been developed, providing protection for at least 5 years and reducing the risk of cervical cancer. J Clin Pathol 2007; 60:961-965.

**Stoler MH.** Human papillomaviruses and cervical neoplasia: a model for carcinogenesis. Int J Gynecol Pathol 2000; 19:16-28.

**Sun XW, Kuhn L, Ellerbrock TV, Chiasson MA, Bush TJ and Wright TC Jr.** Human papillomavirus infection in women infected with the human immunodeficiency virus. N Engl J Med 1997; 337: 1343-9.

---

**The Regence Group Medical Policy.** Laboratory Section: Cervicography. (Website) available at <http://blue.regence.com/trgmedpol/lab/lab13.html>. Accessed 2008.

**Thomas FK.** The FocalPoint System: FocalPoint Slide Profiler and FocalPoint GS. *Cancer (Cancer Cytopathology)* 2004 Dec; 102: 6.

**Ueda M, Ueki K, Kanemura M, et al.** Diagnostic and therapeutic laser conization for cervical intraepithelial neoplasia. *Gynecol Oncol* 2006; 101:143-6.

**Ursin G, Peters RK, Henderson BE, d'Albaing 3rd G, Monroe KR, Pike MC, et al.** Oral contraceptive use and adenocarcinoma of cervix. *Lancet* 1994; 344: 1390-1394.

**Van Doorn LJ, Quint W, Kleter B, et al.** Genotyping of human papillomavirus in liquid cytology cervical specimens by the PGMY line blot assay and the SPF(10) line probe assay. *J Clin Microbiol* 2002; 40:979-83.

**Van Le L, Broekhuizen FF, Janzer-Steele R, Behar M and Samter T.** Acetic acid visualization of the cervix to detect cervical dysplasia. *Obstet Gynecol* 1993; 81:293–5.

**Villa LL, Costa RLR, Petta CA, et al.** Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomized double-blind placebo-controlled multicentre phase II efficacy trial. *Lancet Oncol* 2005; 6: 271-8.

**Villiers EM, Fauquet C, Broker TR, Bernard HU, Zur Hausen H,et al.** Classification of papillomaviruses. *Virology* 2004; 324:17-27.

---

**Vineis RG, Montanari G, Orlassino R, et al.** Impact of the AutoPap (currently FocalPoint) primary screening system location guide use on interpretation time and diagnosis. *Cancer* 2003; 25:83-88.

**Viscidi RP, Kotloff KL, Clayman B, Russ K, Shapiro S and Shah KV.** Prevalence of antibodies to human papillomavirus (HPV) type 16 virus-like particles in relation to cervical HPV infection among college women. *Clin Diagn Lab Immunol* 1997; 4: 122-6.

**Vooijs GP, Elias AG, Van der Graaf Y, and Veling S.** Relationship between the diagnosis of epithelial abnormalities and the composition of cervical smears. *Acta Cytol* 1995; 29: 323-328.

**Wang Q, Griffin H, Southern S, et al.** Functional analysis of the human papillomavirus type 16 E1=E4 protein provides a mechanism for in vivo and in vitro keratin filament reorganization. *J Virol* 2004; 78:821-33.

**Werner CL, Griffith WF, Ashfaq R, Gossett D, Wilkinson E, Raab S, et al.** Comparison of human papillomavirus testing and spectroscopy combined with cervical cytology for the detection of high-grade cervical neoplasia. *J Low Genit Tract Dis* 2007; 11:73-9.

**Wesley R, Sankaranarayanan R, Mathew B, Chandralekha B, Aysha, Beegum A, Amma NS, and Nair MK.** Evaluation of visual inspection as a screening test for cervical cancer. *Br J Cancer* 1997; 75(3): 436-40.

**Willis BH, Barton P, Pearmain P, Bryan S and Hyde C.** Cervical screening programmes: can automation help? Evidence from systematic reviews, an economic analysis and a simulation modelling exercise applied to the UK. *Health Technology Assessment* 2005; 9:13.

---

**Wilson VG, West M, Woytek K and Rangasamy D.** Papillomavirus E1 proteins: form, function, and features. *Virus Genes* 2002; 24:275-90.

**Wolfendale MR, Hoe, Guest R, Usherwood MCD, and Draper GJ.** Controlled trial of a new cervical spatula. *Br Med J* 1997; 298: 33-35.

**Wright VC, Lickrish GM and Michael Shier R.** Basic and Advanced Colposcopy. Part 1: A Practical Handbook for Treatment, 2nd Edition. Houston, Texas: Biomedical Communications, 1995.

**Wright TC, Sun XW and Koulos J.** Comparison of management algorithms for the evaluation of women with low-grade cytological abnormalities. *Obstet Gynecol* 1995; 85:202-210.

**Wright TC Jr, Menton M, Myrtle JF, Chow C and Singer A.** Visualization techniques (colposcopy, direct visual inspection, and spectroscopic and other visual methods). Summary of task force 7. *Acta Cytol* 2002; 46: 793-800.

**Wright TC Jr.** Chapter 10: Cervical Cancer Screening Using Visualization Techniques. *Journal of the National Cancer Institute Monographs* 2003; 31:66-71.

**Wright TC Jr, L Stewart Massad, Charles J Dunton, Mark Spitzer, Edward J. Wilkinson and Diane Solomon.** 2006 consensus guidelines for the management of women with cervical intraepithelial neoplasia or adenocarcinoma in situ, for the 2006 American Society for Colposcopy and Cervical Pathology–sponsored Consensus Conference. *American Journal of Obstetrics and Gynecology* 2007 October; 197(4):340-5.

---

**Young RH and Clement PB.** Endocervical adenocarcinoma and its variants: their morphology and differential diagnosis. *Histopathology* 2002; 41:185-207.

**Zuluoga .**Optical coherence tomography: a new tool for detecting sub surface epithelial abnormalities in vivo. Paper presented at Eurogin Fourth International Multidisciplinary Congress 2000; April 5-9.

**Zur Hausen H.** Papillomaviruses and cancer: from basic studies to clinical application. *Nature Reviews Cancer* 2002; 2: 342-350.